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Abstract: Despite the widespread use of antibodies in clinical applications, the precise molecular
mechanisms underlying antibody–antigen (Ab–Ag) interactions are often poorly understood. In this
study, we exploit the technical features of a typical surface plasmon resonance (SPR) biosensor to
dissect the kinetic and thermodynamic components that govern the binding of single-domain Ab or
nanobodies to their target antigen, epidermal growth factor (EGF), a key oncogenic protein that is
involved in tumour progression. By carefully tuning the experimental conditions and transforming
the kinetic data into equilibrium constants, we reveal the complete picture of binding thermodynamics,
including the energetics of the complex-formation transition state. This approach, performed using
an experimentally simple and high-throughput setup, is expected to facilitate mechanistic studies of
Ab-based therapies and, importantly, promote the rational development of new biological drugs with
suitable properties.
Keywords: nanobodies; SPR; biophysics; thermodynamics; molecular recognition; EGF;
antibody–antigen (Ag–Ab) interactions
1. Introduction
Antibody–antigen (Ab–Ag) interactions are one of the most relevant classes of protein-mediated
molecular recognition processes. They have been selected during millions of years of evolution for
their ability to bind with high specificity and affinity to a wide variety of antigenic molecules [1,2].
From a pharmaceutical perspective, the last decade has witnessed an explosion in the use of Ab for
imaging [3], drug conjugation [4], diagnostic [5] and therapeutic [6] purposes, among many others.
Although the key strengths of Abs are widely recognised in terms of affinity, specificity and biochemical
stability, full-length monoclonal antibodies (mAbs) suffer from some limitations when it comes to their
clinical development, such as undesired Fc-mediated cytotoxicity, poor penetration in target tissues,
aggregation and stability problems, low batch-to-batch reproducibility, and elevated manufacturing
costs, among others [7]. To overcome these issues, a variety of Ab formats have been developed
and optimised in recent years, thanks to the remarkable progress achieved in protein engineering
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and in vitro display methods [8,9]. Among these Ab formats, camelid-derived single-domain Abs,
also known as VHHs or nanobodies, are the smallest Ag-binding proteins found in nature and have
attracted great interest for biotechnological and pharmaceutical applications [10]. Unlike conventional
Abs, nanobodies are formed by a single chain of only ~14 kDa and they can be readily expressed in
recombinant bacteria with high yields [11]. Despite their small size, being one-tenth of a standard IgG
antibody, nanobodies can engage their targets with similar affinities and specificity to full-length Abs.
In addition, compared to mAb, they have a longer variable CDR3 loop, which forms part of a bulging
interface that is ideally suited for targeting cavities, grooves and flexible epitopes [12].
Despite the undeniable progress achieved with the development of therapeutic Abs, there are relatively
few studies shedding light on the kinetics and thermodynamics that drive antigen recognition [13–15].
Moreover, some of these studies have been performed with model systems consisting of full-length
Abs that recognise small-molecule antigens [16,17]. On the contrary, the analysis of pharmacologically
relevant Ab–Ag interactions, at the mechanistic level, is of utmost importance for the success of therapeutic
antibodies during preclinical stages of development.
Protein–protein interactions in general, and antibody–antigen interactions in particular, can be
characterised at several quantitative levels. One of the simplest descriptors is defined by the dissociation
constant (KD), a measure of the strength of the interaction at equilibrium. The KD may be further
resolved into its kinetic descriptors, namely the association (kon) and dissociation (koff) rate constants








Despite being widely used in drug discovery projects, kinetic information alone is insufficient
to fully assess the mechanism of binding interactions [18]. In contrast, thermodynamic parameters
define the state at equilibrium in which Gibbs free energy (G) is the lowest. Large negative changes in
∆G upon binding define a strong molecular interaction. In fact, the relationship between ∆G and the
equilibrium constant (KD) is mathematically described by the Gibbs equation Equation (2). ∆G can be
further decomposed into its enthalpy (∆H) and entropy (∆S) components
∆Go = RTlnKD = ∆Ho − T∆So (2)
In Ab–Ag interactions, binding enthalpy ∆H is associated mainly with the strength and specificity
of the interaction contacts. These are usually related to hydrogen bonds and electrostatic interactions,
although solvent reorganization and conformational change might also have an influence on ∆H.
On the other hand, binding entropy (∆S) reflects the degree of order and disorder of the system
and is often linked to the behaviour of surface-bound water molecules, as well as changes in the
conformational flexibility of the binding partners. Finally, the temperature dependence of ∆H and ∆S
can be defined by changes in the systemic heat capacity (∆Cp), as comprised in the van’t Hoff equation



















Thus, a quantitative assessment of Ab–Ag interactions requires the determination of changes in all
thermodynamic parameters, including ∆G, ∆H, ∆S and ∆Cp. The heat effects (∆H) of an interaction can
be directly measured using isothermal titration calorimetry. However, providing that immobilisation of
the protein does not affect its bioactivity, kinetic and thermodynamic parameters can be also calculated
from the same experimental dataset using a biosensor technique such as surface plasmon resonance
(SPR). Compared to calorimetry measurements, the SPR analysis comes at a much lower time and
protein consumption cost.
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Our group recently reported the discovery of nanobodies against epidermal growth factor
(EGF) [19], a key oncogenic protein involved in the progression of epidermal-based tumours, such as
those of the lung, skin and colon, among others [20]. In the present study, we have leveraged the
potential of SPR for accurately measuring non-covalent interactions at different temperatures and
analyte concentrations to study the kinetics and thermodynamics of two of our leading anti-EGF
targeted nanobodies (Nb1 and Nb6). Our analysis thus provides a valuable case study of the distinct
molecular forces that drive Ag-Ab binding events, with a special emphasis on the behaviour of
single-chain Ab or nanobodies.
2. Results
To probe the interactions of Nb1 and Nb6 with their target antigen, we recombinantly expressed
human EGF [21] and immobilised it by amine coupling on a CM5 sensor chip. Although different
ligand orientations might occur, the three-dimensional dextran hydrogel layer of the chip minimises
steric occlusion of the protein. Furthermore, EGF has been shown to maintain its bioactivity intact
in amine-coupling immobilisation experiments on SPR chips [22]. Low immobilisation levels of
ligand were prioritised (50 and 100 RU, on two different channels) to avoid mass transfer limitations
and re-binding artefacts, as well as unspecific non 1:1 interactions [23]. When injected at increasing
concentrations, both nanobodies produced, as expected, concentration-dependent SPR sensorgrams
and signal saturation at the highest concentrations (Figure 1). We calculated the equilibrium dissociation
constants (KD) at 25 ◦C, by either (I) plotting the level of steady-state binding for each concentration
(i.e., equilibrium fitting, Figure S1); or (II) fitting the association and dissociation signals separately,
as a function of time, to a given interaction model (i.e., kinetic fitting, Figure 1).
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the other hand, the dissociation phase was significantly slower for Nb1. In general, slow binders such 
as Nb1 reach the SPR steady state (i.e., the timepoint at which the net rate of complex formation is 
zero) only after very long injection times. In the case of Nb1, it took 300 s to reach 90% of equilibrium 
at a concentration C equal to its KD (6 nM). Since experimental injection times in SPR are typically 
shorter (in our case, 120 s), more reliable KD values are measured by kinetic fitting, which is 
independent of steady-state levels. It should be noted that these KD values are, to some extent, lower 
Figure 1. Binding kinetics of Nb1 ( ) an b6 ( ) to F at 25 ◦ . anobodies were injected at
increasing concentrations over i obilised EGF, and the association and dissociation phases of
all injections were fitted to a 1:1 Langmuir binding model. Two different surface densities were
used for kon, koff and KD determination, with the corresponding background responses subtracted.
Double-referenced sensorgrams for the highest density channel are shown here. Experiments were
performed in duplicates. Residual errors from the fits are shown in the bottom panels.
For both nanobodies binding to EGF, a 1:1 Lang uir interaction odel had been previously
confirmed by isothermal calorimetry [19]. In agreement, a 1:1 kinetic model provided a close fit to the
experimental data, as shown by the low chi-square values (χ2 = 0.8–2.9). Regarding the association
step, both nanobodies showed fast on-rates (6 and 8 × 105 M−1 s−1 for Nb1 and Nb6, respectively).
On the other hand, the dissociation phase was significantly slower for Nb1. In general, slow binders
such as Nb1 reach the SPR steady state (i.e., the timepoint at which the net rate of complex formation is
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zero) only after very long injection times. In the case of Nb1, it took 300 s to reach 90% of equilibrium at
a concentration C equal to its KD (6 nM). Since experimental injection times in SPR are typically shorter
(in our case, 120 s), more reliable KD values are measured by kinetic fitting, which is independent of
steady-state levels. It should be noted that these KD values are, to some extent, lower than those we
previously reported using a different biosensor method, namely surface acoustic wave (SAW) [19].
However, in the SAW technique, the ligand EGF was immobilised at higher densities using a different
surface chemistry (alkanethiol monolayer, versus the three-dimensional dextran layer used here
for SPR), which could result in mass-transport-limited kinetics, especially for the fastest binders.
These differences might explain why, while the affinity (KD) constants are comparable, SAW-derived
on- and off-rates were about an order of magnitude slower than those calculated here by SPR.
To analyse the variation of kinetics with temperature in more detail, we performed SPR experiments
at temperatures ranging from 9 to 37 ◦C (Figure 2). Binding dissociation followed first-order kinetics at
all temperatures, as shown by the nearly linear logarithmic plots of the dissociation phases (Figure S2).
A 1:1 binding model was applied to extract kon and koff kinetic constants for each analyte concentration
and temperature. The resulting fits, plotted as coloured lines for a single Nb concentration (70 nM) over
a range of temperatures (Figure 2A,B), closely described the experimental data. As expected, the kinetics
slowed dramatically for both Nbs when the temperature was decreased from room temperature to 9 ◦C.
In contrast, faster association and dissociation sensorgrams were observed with heating to human
physiological temperature (37 ◦C). This effect was more pronounced for the dissociation rate, which
translated into an overall drop in the half-life of the complex at the highest temperatures.
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Figure 2. Temperature dependence of binding kinetics and thermodynamic characterisation. Nb1 (A)
and Nb6 (B) were injected over immobilised EGF at the indicated temperatures. For clarity, only
sensorgrams of a single analyte concentration (70 nM) are shown. (C) Van’t Hoff plots representing the
variation of the equilibrium association constants (KA) with the inverse of temperature. Data points
were fitted to a second-order polynomial equation from which ∆G, ∆H, ∆S and ∆Cp values were
determined, following Equation (3). (D) Enthalpy (∆H) and entropy (−T∆S) contributions to the free
energy of binding (∆G) for each Nb at 25 ◦C.
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By representing the change in the equilibrium association constant (KA) as a function of temperature,
in what is known as the van’t Hoff plot Equation (3), one can gain mathematical access to the
thermodynamics of the interaction. In the absence of heat capacity changes, van’t Hoff plots should be
linear and thus discriminate between two terms: an enthalpic contribution that is linear in the inverse
of temperature (1/T), and a temperature-independent entropic contribution. However, significant
curvature in the van’t Hoff plots was observed for both nanobodies at temperatures ranging from
9 to 37 ◦C (Figure 2C). Although there is always a risk of model overfitting to non-ideal SPR data,
the residual values of our global kinetic fitting are very small (see Figure 1, bottom panel). Thus,
the lack of linearity in the van’t Hoff plots reveals instead non-zero heat capacity changes (∆Cp) for the
interactions. The physical reason for the temperature dependence of ∆H is attributed to changes in
solvent-accessible surface areas that are buried in the binding process [24]. In particular, the convex
shape of the van’t Hoff plots is indicative of negative ∆Cp, which might result from the burial of
hydrophobic protein patches upon complex formation.
Non-linear regression using Taylor’s polynomials allowed the determination of the main
thermodynamic parameters for each nanobody (Figure 2D and Table 1). The relative energetic contributions
(∆H and ∆S) are in good agreement with calorimetry data [19]. The binding of Nb1 to EGF was driven
by both entropy and enthalpy components, although there was a strong temperature-dependence for
∆H. Since the tangent to the curve at any point of the van’t Hoff plot is ∆H at that precise temperature,
the decrease in the Nb1 binding enthalpy is especially evident at lower temperatures. In fact, the binding
of Nb1 is purely entropy-driven below 10 ◦C. In a similar fashion, Nb6 showed a convex van’t Hoff plot
indicative of a large negative ∆Cp value (Table 1). However, in contrast to Nb1, Nb6 paid a significant
entropic penalty for binding its antigen, which was largely compensated by a favourable change in ∆H.
As shown here, the negative ∆S is a common feature among most antibodies, since they possess a certain
degree of flexibility in the CDR loops that form the antigen-binding site [25]. Besides being attributed to a
decreased conformational freedom of the complex, the entropic penalty of Nb6 can also be interpreted
in terms of binding to a more hydrophilic epitope on EGF than that of Nb1, thus releasing fewer water
molecules into the bulk solvent.
According to transition state theory [26], the temperature dependence of kon and koff allows
























In a reversible binding process, such as the one studied here, the [EGF-Nb], transition state is
the high energy state along the binding pathway from free species to complex, which is also visited
on the dissociation from the complex to the free species. The thermodynamic approach described
herein provides additional information to the classical ITC studies, since SPR monitors the physical
association and dissociation of the two molecular species, whereas in calorimetric assays the total heat
of the interaction—including heat of dilution or mixing—is measured.
In its graphical representation, it appears that the Eyring plot for Nb1 association (kon) is linear but
significantly dependent on temperature, corresponding to a large activation enthalpy ∆H, (Figure 3A).
The dissociation Eyring plot (representing koff) reveals the curvature that is also present in the van’t Hoff
plot (Figure 2C), as discussed above. In contrast, for Nb6, both association and dissociation Eyring plots
are non-linear (Figure 3B,C). The solution of Eyring’s equation, via Taylor’s series for the non-linear
models provides the transition state thermodynamic parameters (denoted by a superscript “,”).
As shown in Figure 3D, both nanobodies must overcome a significant free energy barrier in order to
bind the target. Although enthalpy drives complex formation in both cases, the transition state of Nb6 is
characterised by a decrease in the association entropy, which indicates that a reduction in conformational
flexibility and structural reordering in the interface is required for binding. This behaviour is in striking
contrast to typical protein–protein interactions, in which the entropic changes are typically favourable
and thus contribute to an increased affinity [27].
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Table 1. Summary of all kinetic and thermodynamic constants.
Id
kon koff K D a K D b ∆Go ∆Ho −T∆So ∆Cop
(M−1 s−1) (s−1) (nM) (nM) (kJ mol−1) (kJ mol−1) (kJ mol−1) (kJ K−1 mol−1)
Nb1-EGF 6.6 × 10
5
± 5 × 103
3.8 × 10−3
± 2 × 10−5
5.8 ± 0.9 16.4 ± 1.2 −47.0 ± 2.2 −44.6 ± 2.4 −2.5 ± 1.9 −2.9 ± 0.5
Nb6-EGF 8.8 × 10
5
± 3 × 104
2.2 × 10−2
± 8 × 10−4
24.3 ± 4.1 30.3 ± 5.3 −43.5 ± 1.4 −78.7 ± 1.4 35.2 ± 1.4 −3.2 ± 0.3
a by means of kinetic fitting; b steady-state or equilibrium fitting.
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Figure 3. Transition state thermodynamics analysis. (A,B) Eyring plots representing the variation of
the association constant (kon) with the inverse of temperature for Nb1 and Nb6. Linear fitting of the
experimental data points to Equation (4) (∆C,p = 0) was performed in (A), while non-linear fitting was
performed in (B). (C) Eyring plots for the dissociationn step of Nb1 and Nb6. Data were fitted to a
second-order polynomial from which the transition state thermodynamic parameters were derived
according to Equation (4). (D) Binding profile of Nb1 and Nb6 illustrating the transitions in ∆G, ∆H,
∆S at 25 ◦C. [EGF–Nb], represents the transition state.
3. Discussion
From a biophysical point of view, the analysis of Ab–Ag interactions is often limited to the
determination of their binding affinity values. These are sometimes complemented with predictive
computational models or high-resolution crystallographic data of the complex. However, the roles of
kinetics and thermodynamics in Ab–Ag molecular recognition are frequently overlooked, and this is
especially the case for the newer types of antibody formats such as single-chain Abs or nanobodies.
However, drawing an analogy with the rational design of small-molecule drugs, it is widely
acknowledged that a more detailed notion of the molecular forces driving the interaction is essential to
fully understand the binding mechanism of the drug and thus be able to implement rational changes
to improve their biological efficacy [28].
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Here, we have interrogated the kinetics and thermodynamics of two anti-EGF nanobodies by
means of surface plasmon resonance (SPR), a technique that is widely implemented in research
laboratories to determine binding affinities. This approach combines high sensitivity and throughput
(it can be readily automated for 96- or 384-microwell formats) with low sample consumption and no
need of labels for the ligand or the analyte, thus allowing the kinetic and thermodynamic profiling of a
large number of preclinical Ab candidates.
Our results show that, for both nanobodies, the formation of the EGF-Ab complex is characterised
by negative changes in enthalpy ∆C and heat capacity ∆Cp (Figure 2D and Table 1), which are caused by
the formation of specific contacts between the two molecules, such as hydrogen bonds and electrostatic
interactions, and might be accompanied by the burial of hydrophobic surface patches (negative ∆Cp).
Furthermore, in contrast to Nb6, binding entropy is favourable for Nb1, which, together with its
extended on-target residence time, might support its development for potential clinical use.
A key differential feature is the much higher entropy penalty of Nb6 in comparison with Nb1,
a difference that already arises in the association step towards the transition state (∆S,), and which is
likely to derive from conformational adjustments of the hypervariable loops at the nanobody binding
interface (Figure 3C). The impact of these distinct energetic profiles on the kinetic behaviour of each
nanobody (fast off-rate koff for Nb6, slow for Nb1) remains an open question. A plausible explanation for
this difference, derived from the Eyring analysis of the Nb1 transition state, is that the large dissociation
activation enthalpy (∆H, = 82.4 kJ/mol) acts as an energetic barrier, preventing the unbinding of Nb1
from the complex once it has formed. Further investigations are nevertheless required.
4. Materials and Methods
Recombinant human EGF (MW = 6.2 kDa) was expressed as previously described [21]
and was immobilised by amine coupling onto a CM5 sensor chip (series S) using the Biacore
T200 (Cytiva, formerly GE Healthcare Life Sciences, Marlborough, MA, USA) at 25 ◦C.
Three different flow cells were independently activated using the regular ratio 1:1 of a 0.4 M
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and a 0.1 M N-hydroxysuccinimide (NHS)
for 7 min at 15 µL/min and phosphate buffer saline (PBS) as running buffer. The ligand (EGF) was
then injected at 1.87 µM in 10 mM acetate buffer pH 4 in channel 2 and 4 in order to achieve 100 and
50 RU, respectively. Considering the size of the SPR chip (0.5 × 2.9 mm = 1.45 mm2), the channel
surface is 0.36 mm2. Since 1 RU ≈ 1 pg/mm2, approximately [29], this results in ≈138 pg of EGF in
our low-density channel, while for the high-density channel, ≈275 pg of EGF were immobilised
(these numbers compare well with the reported EGF concentration in biological media—human
serum EGF is 300–800 pg/mL [30]). The reference channel (flow cell 1) was treated in the same way
but with no ligand (EGF) injected. Finally, channels 1, 2 and 4 were blocked using ethanolamine 1 M
pH 8.5 for 7 min at 15 µL/min. Channel 3 was left unmodified. Nanobodies were freshly expressed
as previously described [19] and used within 1 month of storage at 4 ◦C, to avoid aggregation
artifacts. For affinity, kinetics and thermodynamics experiments, Tween-20 (0.05%) was added to
the PBS running buffer.
Kinetic and affinity experiments were performed at 25 ◦C using a multicycle method, consisting of
short regeneration periods (30 s at 30 µL/min of 50 mM HCl) after each analyte injection. Nanobodies
were serially diluted at a range of concentrations (75 to 5 nM for Nb1, and 100 to 10 nM, for Nb6)
and were injected as analytes for 120 s (followed by 120 s of dissociation) at 30 µL/min. Both high-
and low-density channels were combined for global kinetic fittings (see Supporting Data 1 to 3).
Thermodynamic studies were performed at a range of temperatures—9, 13, 19, 25, 31, and 37 ◦C—on
the ligand high-density channel. All experiments were performed in duplicate. The resulting
sensorgrams were double referenced and fitted to 1:1 Langmuir binding model using Biacore T200
Evaluation Software version 3.1.
Determination of the kinetic and thermodynamic parameters was performed as described below,
by fitting the data to Equations (3) and (4) using GraphPad Prism 8 software (see Supporting Data 4
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to 7). In Equations (1)–(4), KD is the affinity constant (also equilibrium dissociation constant), KA is the
equilibrium association constant, kon and koff are the kinetic association and dissociation constants,
respectively. ∆Go, ∆Ho, ∆So and ∆Cop are the Gibs free energy, enthalpy, entropy and heat capacity
changes under standard conditions (the superscript “o” denotes the standard state: 1 atm and 298.15 K;
while “,” refers to the transition state). In Eyring’s equation Equation (4), kB is Boltzmann’s constant
(1.381 × 10−23 J K−1) and h is Plank’s constant (6.626 × 10−34 J s).
5. Conclusions
Our results demonstrate that a comprehensive Ab–Ag interaction analysis, based on thermodynamic
and kinetic parameters, can be obtained in a straightforward manner from an SPR biosensor setup.
This methodology will prove to be valuable for identifying the underlying structural, thermodynamic and
kinetic clues employed by nature-evolved antibodies to recognise their cognate antigens. In addition, since
mAb and other Ab formats have currently become one of the most important classes of pharmaceutical
agents, we believe that this type of mechanistic analysis will enable researchers to rationally design and
engineer improved antibodies with higher affinity, specificity and biochemical stability.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/13/6/134/s1,
Figure S1: SPR equilibrium responses of Nb1 (A) and Nb6 (B) at a range of concentrations. KD values resulting from
non-linear curve fitting to a 1:1 Langmuir model are reported in Table 1 (main text).; Figure S2: Semilogarithmic
plots of the dissociation phases for Nb1 (A) and Nb6 (B) at 50 nM over a range of temperatures, indicating that
dissociation largely follows first-order kinetics at each temperature (note the exception for Nb6 at 37 ◦C, with a
very fast dissociation that deviates from linearity).
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